{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:32:37Z","timestamp":1790865157759,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Progetto Ateneo Sapienza"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a prospective study on the clinical outcome and antiviral effects of mAbs added to standard of care therapy in SARS-CoV-2-infected patients with primary antibody defects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median time of SARS-CoV-2 quantitative polymerase chain reaction (qPCR) positivity was shorter in 8 patients treated with mAbs (22 days) than in 10 patients treated with standard of care therapy only (37 days, P=.026). Median time of SARS-CoV-2 qPCR positivity from mAb administration was 10 days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The SARS-CoV-2 mAbs treatment was effective and well tolerated in patients with primary antibody defects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiab554","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T12:11:08Z","timestamp":1636114268000},"page":"820-824","source":"Crossref","is-referenced-by-count":12,"title":["Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency"],"prefix":"10.1093","volume":"225","author":[{"given":"Federica","family":"Pulvirenti","sequence":"first","affiliation":[{"name":"Primary Immune Deficiencies Unit, Azienda Ospedaliera Universitaria Policlinico Umberto I, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Milito","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cinetto","sequence":"additional","affiliation":[{"name":"Department of Medicine-DIMED, University of Padova, and Internal Medicine I, Ca\u2019 Foncello Hospital, AULSS2 Marca Trevigiana, Treviso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane","family":"Fernandez Salinas","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome and Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Terreri","sequence":"additional","affiliation":[{"name":"Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Piano Mortari","sequence":"additional","affiliation":[{"name":"Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Auria","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Soccodato","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichtner","family":"Miriam","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy"},{"name":"Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Nicastri","sequence":"additional","affiliation":[{"name":"National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vincenzi","sequence":"additional","affiliation":[{"name":"POIT-INMI Spallanzani Infectious Diseases\/Hepatology Unit, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Carsetti","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome and Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpiero","family":"D\u2019Offizi","sequence":"additional","affiliation":[{"name":"POIT-INMI Spallanzani Infectious Diseases\/Hepatology Unit, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Quinti","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"2022030208292836200_CIT0001","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: an international study.","volume":"147","author":"Meyts","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2022030208292836200_CIT0002","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaip.2020.09.052","article-title":"Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City.","volume":"9","author":"Ho","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2022030208292836200_CIT0003","first-page":"S2213-2198(21)00457-8","article-title":"Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity.","author":"Milito","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2022030208292836200_CIT0004","doi-asserted-by":"crossref","DOI":"10.1097\/ACI.0000000000000789","article-title":"COVID-19 in complex common variable immunodeficiency patients affected by lung diseases.","author":"Milito","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2022030208292836200_CIT0005","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host.","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med"},{"key":"2022030208292836200_CIT0006","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.jinf.2020.04.026","article-title":"How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? a systematic review.","volume":"81","author":"Minotti","year":"2020","journal-title":"J Infect"},{"key":"2022030208292836200_CIT0007","first-page":"1","article-title":"SARS-CoV-2 vaccine q defects: everybody does their best.","volume":"20","author":"Salinas","year":"2021","journal-title":"J Clin Immunol"},{"key":"2022030208292836200_CIT0008","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ijpara.2020.08.003","article-title":"Potential functions of atypical memory B cells in Plasmodium-exposed individuals.","volume":"50","author":"Braddom","year":"2020","journal-title":"Int J Parasitol"},{"key":"2022030208292836200_CIT0009","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1093\/infdis\/jiaa593","article-title":"No SARS-CoV-2 neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic.","volume":"222","author":"Schwaiger","year":"2020","journal-title":"J Infect Dis"},{"key":"2022030208292836200_CIT0010","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe Covid-19 in older adults.","volume":"384","author":"Libster","year":"2021","journal-title":"N Engl J Med"},{"key":"2022030208292836200_CIT0011","doi-asserted-by":"crossref","first-page":"655896","DOI":"10.3389\/fcimb.2021.655896","article-title":"IgA antibodies and IgA deficiency in SARS-CoV-2 infection.","volume":"11","author":"Quinti","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2022030208292836200_CIT0012","doi-asserted-by":"crossref","first-page":"596761","DOI":"10.3389\/fimmu.2020.596761","article-title":"Case report: convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19.","volume":"11","author":"Van Damme","year":"2020","journal-title":"Front Immunol"},{"key":"2022030208292836200_CIT0013","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41587-020-0512-5","article-title":"Developing therapeutic monoclonal antibodies at pandemic pace.","volume":"38","author":"Kelley","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2022030208292836200_CIT0014","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1016\/j.cell.2021.05.005","article-title":"Tackling COVID-19 with neutralizing monoclonal antibodies.","volume":"184","author":"Corti","year":"2021","journal-title":"Cell"},{"key":"2022030208292836200_CIT0015","first-page":"ciab494","article-title":"Outpatient treatment of SARS-CoV-2 infection to prevent COVID-19 progression.","author":"Cohen","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab554\/41881232\/jiab554.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/5\/820\/42662138\/jiab554.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/5\/820\/42662138\/jiab554.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T08:30:20Z","timestamp":1646209820000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/5\/820\/6423060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,11,8]]},"published-print":{"date-parts":[[2022,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab554","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,11,8]]}}}